Quality Control Analysis of Mesenchymal Stem/Stromal Cells During
Investigational New Drug Application for GvHD Administration in China

Aitong      Wang; Leisheng      Zhang; Meng      Zhao; Hao      Yu

doi:10.2174/1574888X17666220520155212

Abstract

Graft-versus-host disease (GvHD), including the acute and chronic types (aGvHD, cGvHD), arise as the dominating secondary disease in patients with unsatisfying consequences of allogeneic hematopoietic stem cell transplantation (HSCT). Approximately half of GvHD patients were steroid-resistant, with a two-year overall survival rate lower than 20%. Worse still, there are no standardized criteria for an optimal second-line therapy for steroid-resistant aGVHD patients. Notably, pioneering investigators have highlighted the ameliorative or therapeutic effects of human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) upon GvHD largely attributed to their unique hematopoietic-supporting and immunomodulatory properties. Of note, quality control (QC) is the prerequisite to assure the safety and quality of hUC-MSCs before investigational new drug (IND) applications and large-scale clinical applications. Herein, we summarize the state-of-the-art updates upon IND-associated QC and clinical trials of hUC-MSCs during allogeneic HSCT in China. Meanwhile, the supervisory policy and medical ethics of current licensed MSC products for GvHD administration and the concomitant opportunities and challenges have also been discussed.

Keywords: UC-MSCs, GvHD, QC, Clinical trials, HSCT, stem cell transplantation.

« Previous Next »

Graphical Abstract

[1]
Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X. Progress in hematopoietic stem cell transplantation for CIDP. Int J Med Sci  2020; 17(2): 234-41.
 [http://dx.doi.org/10.7150/ijms.38363] [PMID:  32038107]

[2]
Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis. Lancet Haematol  2016; 3(1): e45-52.
 [http://dx.doi.org/10.1016/S2352-3026(15)00224-0] [PMID:  26765648]

[3]
Gooptu M, Antin JH. GVHD prophylaxis 2020. Front Immunol  2021; 12: 605726.
 [http://dx.doi.org/10.3389/fimmu.2021.605726] [PMID:  33897681]

[4]
McGuirk JP, Smith JR, Divine CL, Zuniga M, Weiss ML. Wharton’s jelly-derived mesenchymal stromal cells as a promising cellular therapeutic strategy for the management of graft-versus-host disease. Pharmaceuticals (Basel)  2015; 8(2): 196-220.
 [http://dx.doi.org/10.3390/ph8020196] [PMID:  25894816]

[5]
Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Cytotherapy  2016; 18(2): 172-85.
 [http://dx.doi.org/10.1016/j.jcyt.2015.11.010] [PMID:  26794711]

[6]
Pavletic SZ, Smith LM, Bishop MR, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol  2005; 78(4): 265-74.
 [http://dx.doi.org/10.1002/ajh.20275] [PMID:  15795914]

[7]
Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood  2012; 119(1): 296-307.
 [http://dx.doi.org/10.1182/blood-2011-06-364265] [PMID:  22010102]

[8]
Burnham AJ, Daley-Bauer LP, Horwitz EM. Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv  2020; 4(22): 5877-87.
 [http://dx.doi.org/10.1182/bloodadvances.2020002646] [PMID:  33232479]

[9]
Wei Y, Zhang L, Chi Y, et al. High-efficient generation of VCAM-1+ mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice. Cell Prolif  2020; 53(8): e12862.
 [http://dx.doi.org/10.1111/cpr.12862] [PMID:  32597552]

[10]
Huo J, Zhang L, Ren X, et al. Multifaceted characterization of the signatures and efficacy of mesenchymal stem/stromal cells in acquired aplastic anemia. Stem Cell Res Ther  2020; 11(1): 59.
 [http://dx.doi.org/10.1186/s13287-020-1577-2] [PMID:  32054519]

[11]
Borella G, Da Ros A, Borile G, et al. Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood  2021; 138(7): 557-70.
 [http://dx.doi.org/10.1182/blood.2020009845] [PMID:  34010415]

[12]
Tan SHS, Kwan YT, Neo WJ, et al. Intra-articular injections of mesenchymal stem cells without adjuvant therapies for knee osteoarthritis: A systematic review and meta-analysis. Am J Sports Med  2021; 49(11): 3113-24.
 [http://dx.doi.org/10.1177/0363546520981704] [PMID:  33471552]

[13]
Ge M, Zhang Y, Hao Q, Zhao Y, Dong B. Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta-analysis. Brain Behav  2018; 8(7): e00982.
 [http://dx.doi.org/10.1002/brb3.982] [PMID:  29877067]

[14]
Wang R, Yao Q, Chen W, et al. Stem cell therapy for Crohn’s disease: Systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther  2021; 12(1): 463.
 [http://dx.doi.org/10.1186/s13287-021-02533-0] [PMID:  34407875]

[15]
Chen B, Wang YH, Qian JQ, Wu DB, Chen EQ, Tang H. Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: A systematic review with meta-analysis. Eur J Gastroenterol Hepatol  2018; 30(10): 1224-9.
 [http://dx.doi.org/10.1097/MEG.0000000000001156] [PMID:  29727380]

[16]
Morata-Tarifa C, Macías-Sánchez MDM, Gutiérrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther  2020; 11(1): 64.
 [http://dx.doi.org/10.1186/s13287-020-01592-z] [PMID:  32070420]

[17]
Lalu MM, Mazzarello S, Zlepnig J, et al. Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (safecell heart): A systematic review and meta-analysis. Stem Cells Transl Med  2018; 7(12): 857-66.
 [http://dx.doi.org/10.1002/sctm.18-0120] [PMID:  30255989]

[18]
Wei Y, Hou H, Zhang L, et al. JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia. Stem Cell Res Ther  2019; 10(1): 186.
 [http://dx.doi.org/10.1186/s13287-019-1302-1] [PMID:  31234947]

[19]
Zhao Q, Zhang L, Wei Y, et al. Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease. Stem Cell Res Ther  2019; 10(1): 354.
 [http://dx.doi.org/10.1186/s13287-019-1478-4] [PMID:  31779707]

[20]
Deuse T, Stubbendorff M, Tang-Quan K, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant  2011; 20(5): 655-67.
 [http://dx.doi.org/10.3727/096368910X536473] [PMID:  21054940]

[21]
Markov A, Thangavelu L, Aravindhan S, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther  2021; 12(1): 192.
 [http://dx.doi.org/10.1186/s13287-021-02265-1] [PMID:  33736695]

[22]
Wu KH, Chan CK, Tsai C, et al. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation  2011; 91(12): 1412-6.
 [http://dx.doi.org/10.1097/TP.0b013e31821aba18] [PMID:  21494176]

[23]
Wu KH, Sheu JN, Wu HP, et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: A pilot study. Transplantation  2013; 95(5): 773-7.
 [http://dx.doi.org/10.1097/TP.0b013e31827a93dd] [PMID:  23274973]

[24]
Wu KH, Tsai C, Wu HP, Sieber M, Peng CT, Chao YH. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: Enhance hematopoiesis after cord blood transplantation. Cell Transplant  2013; 22(11): 2041-51.
 [http://dx.doi.org/10.3727/096368912X663533] [PMID:  24165586]

[25]
Wu Y, Wang Z, Cao Y, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. Ann Hematol  2013; 92(12): 1675-84.
 [http://dx.doi.org/10.1007/s00277-013-1831-0] [PMID:  23842707]

[26]
Wu Y, Cao Y, Li X, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: Successful engraftment and mild GVHD. Stem Cell Res (Amst)  2014; 12(1): 132-8.
 [http://dx.doi.org/10.1016/j.scr.2013.10.001] [PMID:  24185180]

[27]
Li XH, Gao CJ, Da WM, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One  2014; 9(3): e89666.
 [http://dx.doi.org/10.1371/journal.pone.0089666] [PMID:  24594618]

[28]
Si Y, Yang K, Qin M, et al. Efficacy and safety of human umbilical cord derived mesenchymal stem cell therapy in children with severe aplastic anemia following allogeneic hematopoietic stem cell transplantation: a retrospective case series of 37 patients. Pediatr Hematol Oncol  2014; 31(1): 39-49.
 [http://dx.doi.org/10.3109/08880018.2013.867556] [PMID:  24383400]

[29]
Gao L, Zhang Y, Hu B, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol  2016; 34(24): 2843-50.
 [http://dx.doi.org/10.1200/JCO.2015.65.3642] [PMID:  27400949]

[30]
Wang X, Zhang M, He P. Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. J Int Med Res  2020; 48(5): 300060520920438.
 [http://dx.doi.org/10.1177/0300060520920438] [PMID:  32363972]

[31]
Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant  2009; 15(7): 804-11.
 [http://dx.doi.org/10.1016/j.bbmt.2008.03.012] [PMID:  19539211]

[32]
Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant  2011; 17(4): 534-41.
 [http://dx.doi.org/10.1016/j.bbmt.2010.04.014] [PMID:  20457269]

[33]
Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant  2014; 20(2): 229-35.
 [http://dx.doi.org/10.1016/j.bbmt.2013.11.001] [PMID:  24216185]

[34]
Kurtzberg J, Prockop S, Chaudhury S, et al. Study 275: Updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children. Biol Blood Marrow Transplant  2020; 26(5): 855-64.
 [http://dx.doi.org/10.1016/j.bbmt.2020.01.026] [PMID:  32044400]

[35]
Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: A phase I/II study. Int J Hematol  2013; 98(2): 206-13.
 [http://dx.doi.org/10.1007/s12185-013-1399-4] [PMID:  23860964]

[36]
Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: A phase II/III study. Int J Hematol  2016; 103(2): 243-50.
 [http://dx.doi.org/10.1007/s12185-015-1915-9] [PMID:  26608364]

[37]
Miyamura K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: Need of follow up for some remaining concerns. Int J Hematol  2016; 103(2): 155-64.
 [http://dx.doi.org/10.1007/s12185-015-1930-x] [PMID:  26759322]

[38]
Hyun I, Lindvall O, Ahrlund-Richter L, et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell  2008; 3(6): 607-9.
 [http://dx.doi.org/10.1016/j.stem.2008.11.009] [PMID:  19041777]

[39]
King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther  2014; 5(4): 85.
 [http://dx.doi.org/10.1186/scrt474] [PMID:  25157428]

[40]
Fink DW Jr. FDA regulation of stem cell-based products. Science  2009; 324(5935): 1662-3.
 [http://dx.doi.org/10.1126/science.1173712] [PMID:  19556496]

[41]
Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. N Engl J Med  2018; 378(10): 954-9.
 [http://dx.doi.org/10.1056/NEJMsr1715626] [PMID:  29514023]

[42]
Corbett MS, Webster A, Hawkins R, Woolacott N. Innovative regenerative medicines in the EU: a better future in evidence? BMC Med  2017; 15(1): 49.
 [http://dx.doi.org/10.1186/s12916-017-0818-4] [PMID:  28270209]

[43]
Konomi K, Tobita M, Kimura K, Sato D. New Japanese initiatives on stem cell therapies. Cell Stem Cell  2015; 16(4): 350-2.
 [http://dx.doi.org/10.1016/j.stem.2015.03.012] [PMID:  25842974]

[44]
Cyranoski D. China announces stem-cell rules. Nature  2015; 27.

[45]
Yuan BZ. The law-regulation-guidance regulatory system for stem cell-based medicinal products. Chin Bull Life Sci  2016; 28: 949-56.

[46]
Center for drug evaluation, national medical products administration, technical guidance for the research and review of cell therapy products. 2017.

Rights & Permissions Print Cite

Article Metrics

4

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574888X17666220520155212	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946

Current Stem Cell Research & Therapy

Quality Control Analysis of Mesenchymal Stem/Stromal Cells During Investigational New Drug Application for GvHD Administration in China

Abstract Play Pause

Graphical Abstract

Related Books

Abstract